Black Diamond Therapeutics Q1 2022 Earnings Report
Key Takeaways
Black Diamond Therapeutics reported its Q1 2022 financial results, highlighting the dosing of the first patient in the Phase 1 study of BDTX-1535 and the extension of the cash runway into Q3 2024 through pipeline prioritization and resource realignment. The company's cash, cash equivalents, and investments amounted to approximately $179.7 million as of March 31, 2022.
First patient dosed in Phase 1 Study of BDTX-1535 for GBM and NSCLC.
Strategic focus on development of BDTX-1535, BDTX-4933, and MAP drug discovery engine.
Financial position strengthened, extending cash runway into Q3 2024.
Cash, cash equivalents, and investments of approximately $179.7 million as of March 31, 2022.
Black Diamond Therapeutics
Black Diamond Therapeutics
Forward Guidance
Following the Company’s pipeline prioritization and workforce realignment announcement in April 2022, Black Diamond has extended its cash runway which is expected to be sufficient to fund its anticipated operating expenses and expenditure requirements into the third quarter of 2024.